Evidence map›Paper›PMID 28012857›Full record

ArticlePeptides2017

An enzymatic assay based on luciferase Ebola virus-like particles for evaluation of virolytic activity of antimicrobial peptides.

Marie Peskova, Zbynek Heger, Petr Janda, Vojtech Adam, Vladimir Pekarik

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Peptides, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Therapeutic Bioactivity Exerted by theMolecules (Basel, Switzerland) · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Marie PeskovaCentral European Institute of Technology (CEITEC), Masaryk University, Kamenice 5, 625 00 Brno, Czechia. Electronic address: m.peskova@mail.muni.cz.
Zbynek HegerDepartment of Chemistry and Biochemistry, Mendel University, 613 00 Brno, Czechia; Central European Institute of Technology (CEITEC), Brno University of Technology, 616 00 Brno, Czechia. Electronic address: zbynek.heger@mendelu.cz.
Petr JandaCentral European Institute of Technology (CEITEC), Masaryk University, Kamenice 5, 625 00 Brno, Czechia. Electronic address: 323853@mail.muni.cz.
Vojtech AdamDepartment of Chemistry and Biochemistry, Mendel University, 613 00 Brno, Czechia; Central European Institute of Technology (CEITEC), Brno University of Technology, 616 00 Brno, Czechia. Electronic address: vojtech.adam@mendelu.cz.
Vladimir PekarikCentral European Institute of Technology (CEITEC), Masaryk University, Kamenice 5, 625 00 Brno, Czechia; Institute of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czechia. Electronic address: pekarikv@mail.muni.cz.
Central European Institute of Technology · CZBrno University of Technology · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial peptides are currently considered as promising antiviral compounds. Current assays to evaluate the effectivity of peptides against enveloped viruses based on liposomes or hemolysis are encumbered by the artificial nature of liposomes or distinctive membrane composition of used erythrocytes. We propose a novel assay system based on enzymatic Ebola virus-like particles containing sensitive luciferase reporter. The assay was validated with several cationic and anionic peptides and compared with lentivirus inactivation and hemolytic assays. The assay is sensitive and easy to perform in standard biosafety level laboratory with potential for high-throughput screens. The use of virus-like particles in the assay provides a system as closely related to the native viruses as possible eliminating some issues associated with other more artificial set ups. We have identified CAM-W (KWKLWKKIEKWGQGIGAVLKWLTTWL) as a peptide with the greatest antiviral activity against infectious lentiviral vectors and filoviral virus-like particles.

Indexed as

AnionsAntimicrobial Cationic PeptidesAntiviral AgentsEbolavirusHemorrhagic Fever, EbolaHumansLentivirusLiposomesPeptidesVaccines, Virus-Like ParticleAnionsAntimicrobial Cationic PeptidesAntiviral AgentsLiposomesPeptidesVaccines, Virus-Like ParticleAntimicrobial peptidesCytotoxic peptidesEbolaHemolytic activityLentivirusMarburgNanoluciferaseVirolytic activityVirus-like particles

Identifiers

PMID28012857
PMCPMC7115697
OpenAlexW2561166813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.